Partnering With The VA: Otsuka’s Opt-In Agenda

Otsuka's John Bardi on the potential of partnerships with the VA’s ORD division.

To obtain a clear-eyed view of the current state of partnering between biopharma companies and the VA, In Vivo spoke with John Bardi, vice-president of government affairs for Otsuka America Pharmaceutical Inc. Otsuka, a key player in the CNS therapeutic space, is interested in the potential of tie-ups between its research operations and the VA’s ORD division. In doing so, the company emphasizes the importance of addressing two logistical factors close to the heart of every innovative drug developer: quality and speed.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By 

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By 

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.